It is unclear what constitutes a clinically meaningful response for allergic rhinitis (AR) outcomes.
Dymista (azelastine hydrochloride and fluticasone propionate) from Meda AB has received medical approval in Europe via the decentralized registration procedure....
The aims of this study were (1) to characterise the type of patient prescribed MP-AzeFlu (Dymista, a novel formulation of azelastine hydrochloride, fluticasone propionate and excipients in a single spray) in real life in the UK and...
Objective: To compare fluticasone propionate aqueous nasal spray, 200 microg daily, with oral montelukast, 10 mg daily, for the relief of SAR symptoms.